Boule Diagnostics operates in the medical technology industry and focuses on the development and manufacture of diagnostic instruments for hematology. The company's products are aimed at healthcare institutions and laboratories. The business is global with a main presence in Europe, North America and Asia. Boule Diagnostics was founded in 1956 and is headquartered in Spånga, Sweden.
Beat on adj. EBIT but lower OCF Adj. EBIT up 8.9-9.8% for '25e-'26e Trading at 5.6x '25e EV/EBIT Higher volume but lower ASP Boule Diagnostics ended the year with sales of SEK 143.2m (+2% vs. ABGSCe 140.6m), organic growth of -1.8% (ABGSCe -4.3%), a ...
Adj. EBIT +85% vs ABGSCe Soft cash flow generation Estimates likely up 10% on adj. EBIT Q4 results Net sales came at SEK 143.2m (+2% vs. ABGSCe 140.6m) with organic growth of -1.8% (ABGSCe -4.3%). The gross margin was 44.6% (ABGSCe 47.1%). Q4 adj. EBIT...
Q4'24 results due 11 February '25e-'26e adj. EBIT revised by 0.5-0.7% Share trading at '25e EV/EBIT of 6.3x Q4'24 expectations We expect Boule Diagnostics to deliver organic sales growth of -4% to SEK 141m in Q4'24e. Consumables performed well in Q3,...
- Adj. EBIT better but OCF down in Q3 - Transition in progress - Adj. EBIT up 7% in '24e, down 1% in '25e-'26e Mixed Q3 Boule Diagnostics reported a mixed set of numbers in Q3 with weaker-than-expected sales (-4% vs ABGSCe) but a higher gross margin ...
- Weak on sales but higher gross margin - More restrucrings to come - Estimates likely up 5-10% on adj. EBIT Q3 results Net sales came at SEK 130.4m (-4% vs. ABGSCe 136.3m) with organic growth of -2% (ABGSCe -1.0%). The gross margin was 46.8% (ABGSCe...
Q3'24 results due 25 October '24e-'26e adj. EBIT revised down 0.7%-1.3% We forecast -1% organic growth and 7.7% adj. EBIT margin Q3'24 expectations We expect Boule Diagnostics to report organic sales growth of -1% in Q3'24 and adj. EBIT of SEK 10.5m ...
- Weak Q2, -6% on sales and -25% on adj. EBIT vs ABGSCe - FCF generation held back by R&D capitalisation - We cut '24e adj. EBIT by 6.7% Soft Q2 numbers Boule Diagnostics reported weaker-than-expected Q2 results, mainly due to lower sales and gross margin...
- 25% miss on adj EBIT - Lower on sales and weaker gross margin - Estimates likely down 5-8% on adj. EBIT Q2 results Net sales came at SEK 137m (-6% vs. ABGSCe 146.4m) with organic growth of -3.6% (ABGSCe +3.3%). The gross margin was 43.1% (ABGSCe 45...
- Q2'24 results due 22 July- 24e-'26e EBIT revised down 1.0-2.1%- We expect 3.3% organic growth and 9.0% EBIT margin Q2'24 expectations We expect Boule Diagnostics to report an organic sales growth of 3.3% in Q2'24 and an EBIT margin of 9.0%, up from...
Solid earnings beat in Q1 Launch of new system delayed '24e EBIT revised up 8.6%, +0.3-1.1% for '25e-'26e Strong start to the year in Q1... Boule Diagnostics reported a strong set of numbers in Q1 with a 43% beat on reported EBIT, but with disappointing...
43% beat on EBIT Expected launch of new product delayed EBIT '24e expected to be revised up 7-10% Q1 results Net sales came at SEK 147.8m (-1% vs. ABGSCe 149.2m) but with organic growth of +5.4%, compared to ABGSCe at +4.3%. Q1 EBIT of SEK 15.4m (+43...
Q1'24 results due 7 May '24e-'26e EBIT up 0.8-1.6% due to FX 29-39% below historical NTM P/E and NTM EV/EBIT Q1'24e expectations We forecast 4.3% organic growth in Q1 and EBIT of SEK 10.7m, down from SEK 12.1m in '23e due to an estimated SEK 3m in non...
Underlying earnings better than expected 4.2% organic sales growth in Q4 Near-term uncertainty persists, but long-term potential unchanged Q4 negatively impacted by one-offs Boule Diagnostics delivered another quarter with positive organic growth in ...
Q4'23 results due 6 February Instrument sales to drive growth in Q4e 27-33% below historical NTM P/E and NTM EV/EBITDA Q4'23e expectations We expect Boule Diagnostics to report +2.4% organic sales growth and an EBIT margin of 8.2% in Q4'23e, up from ...
4.3% organic sales growth Improved cash flow generation Near-term uncertainty, but long-term potential unchanged Improved sales growth, but lower gross margin Boule Diagnostic returned to positive organic growth in Q3 after four consecutive quarters ...
- Geopolitical situation compromises Boule's performance - 5-part system sales pushed to '25 due to need for improvements - Short-term uncertainty, but still promising long-term outlook Geopolitical situation brings uncertainty The global geopolitical...